SCHEMBL2005000

SCHEMBL2005000

Cc1cc(S(=O)(=O)Nc2cc(Cl)cc(Oc3nc4ccc(F)cc4s3)c2)c(Cl)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.44
RORC P51449 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 2/20 0.40
PPARG P37231 2/20 0.40
CYP3A4 P08684 1/20 0.40
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
KMT2A Q03164 3/20 0.37
NPC1 O15118 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CTSD P07339 1/20 0.37
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001848 0.92 RORC (0.42) RORCSMN1; SMN2LMNAHTTPPARG
SCHEMBL2003335 0.90 TP53 (0.44) SMN1; SMN2LMNAHTTPPARGCYP3A4
SCHEMBL1996053 0.88 PPARG (0.48) FSCN1PPARGCYP3A4
SCHEMBL2004626 0.87 LMNA (0.41) LMNAHTTPPARGCYP3A4MEN1
SCHEMBL2002294 0.84 PPARG (0.49) FSCN1RORCPPARGCYP3A4PTGDR2
SCHEMBL2006350 0.83 LMNA (0.42) LMNAHTTPPARGCYP3A4MEN1
SCHEMBL1999994 0.83 FBP1 (0.41) LMNAPPARGCYP3A4MEN1KMT2A
SCHEMBL2003942 0.83 PPARG (0.40) LMNAPPARGCYP3A4MEN1KMT2A
SCHEMBL2002150 0.82 PPARG (0.39) LMNAHTTPPARGCYP3A4MAPT
SCHEMBL2004784 0.82 PPARG (0.50) PPARGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD FSCN1 4835/4885RORC 42/4885SMN1; SMN2 4885/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD FSCN1 4835/4885RORC 42/4885SMN1; SMN2 4885/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD FSCN1 4835/4885RORC 42/4885SMN1; SMN2 4885/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD FSCN1 4826/4885RORC 35/4885SMN1; SMN2 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.